Novozymes (NSIS B) Stock Overview
Produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
NSIS B Community Fair Values
Create NarrativeSee what 40 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Novozymes A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 424.50 |
| 52 Week High | DKK 465.00 |
| 52 Week Low | DKK 336.80 |
| Beta | 0.63 |
| 1 Month Change | 1.39% |
| 3 Month Change | 9.69% |
| 1 Year Change | 5.60% |
| 3 Year Change | 41.41% |
| 5 Year Change | -12.53% |
| Change since IPO | 1,210.19% |
Recent News & Updates
NSIS B: India Capacity Expansion Will Shape Long Term Upside Potential
The analyst fair value estimate for Novozymes is now DKK 491.93, up DKK 20.88 from the prior DKK 471.06. Analysts are factoring in updated assumptions that align with a series of recent price target increases on Novonesis in the DKK 490 to DKK 535 range.
NSIS B: Elevated Expectations Will Hinge On Successful MicroBioGen Integration
The analyst fair value estimate for Novozymes has been raised from DKK 400 to DKK 414. This change reflects a series of higher DKK 415 to DKK 535 price targets from several firms, along with analyst views that support slightly stronger margin and P/E assumptions despite a marginally higher discount rate and modestly softer revenue growth inputs.Recent updates
NSIS B: India Capacity Expansion Will Shape Long Term Upside Potential
The analyst fair value estimate for Novozymes is now DKK 491.93, up DKK 20.88 from the prior DKK 471.06. Analysts are factoring in updated assumptions that align with a series of recent price target increases on Novonesis in the DKK 490 to DKK 535 range.NSIS B: Elevated Expectations Will Hinge On Successful MicroBioGen Integration
The analyst fair value estimate for Novozymes has been raised from DKK 400 to DKK 414. This change reflects a series of higher DKK 415 to DKK 535 price targets from several firms, along with analyst views that support slightly stronger margin and P/E assumptions despite a marginally higher discount rate and modestly softer revenue growth inputs.
NSIS B: Consumer Health Probiotics Expansion Will Support Higher Multiple Potential
The analyst fair value estimate for Novozymes has increased from DKK 520 to DKK 540, as analysts cite a series of higher Street price targets in the DKK 460 to DKK 552 range and improving views on the company following recent rating upgrades. Analyst Commentary on Novozymes Recent research on Novozymes, through the merged Novonesis entity, points to a more constructive tone from several bullish analysts.NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Higher Multiple Potential
The analyst price target for Novozymes has been reset to DKK 520, with analysts pointing to updated assumptions on growth, profitability and valuation multiples as the main drivers of the change. Analyst Commentary Recent Street research on Novozymes, now part of Novonesis, shows a series of constructive shifts in sentiment, with several firms revisiting their assumptions on valuation, execution and growth.NSIS B: Fair Outlook Will Rely On Probiotic Expansion In China
The analyst fair value estimate for Novozymes has been raised from DKK 380 to DKK 400, reflecting a series of higher Street price targets from multiple firms as analysts point to updated views on growth, margins and valuation for Novonesis. Analyst Commentary Recent Street research on Novozymes and Novonesis highlights a mix of optimism on long term potential and caution around execution and valuation risk.NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Premium Multiple
Analysts have nudged the fair value estimate for Novozymes (Novonesis) slightly lower to DKK 548.58 from about DKK 560, reflecting a blend of trimmed Street price targets around DKK 552 and DKK 460, as well as updated assumptions for revenue growth, profit margins and a more conservative future P/E of 34x. Analyst Commentary Recent Street research on Novozymes reflects a mix of fine tuning on price targets and ratings, with bullish analysts focusing on the company’s positioning in consumer ingredients and its ability to support premium valuation metrics.Novozymes (CPSE:NSIS B) Stock Could Be 31% Below Fair Value After UndoAge Deal
UndoAge partnership puts Novozymes (CPSE:NSIS B) in focus The new Memorandum of Understanding between UndoAge and Novonesis to co develop probiotics and postbiotics for the Chinese consumer health market puts fresh attention on Novozymes stock for investors tracking microbiome related opportunities. See our latest analysis for Novozymes. At a share price of DKK394.2, Novozymes has seen momentum build recently, with a 30 day share price return of 5.40% and a 90 day gain of 12.44%, even as the...Shareholder Returns
| NSIS B | DK Chemicals | DK Market | |
|---|---|---|---|
| 7D | -5.8% | -1.4% | -1.8% |
| 1Y | 5.6% | 9.1% | 0.1% |
Return vs Industry: NSIS B underperformed the Danish Chemicals industry which returned 9.1% over the past year.
Return vs Market: NSIS B exceeded the Danish Market which returned 0.1% over the past year.
Price Volatility
| NSIS B volatility | |
|---|---|
| NSIS B Average Weekly Movement | 4.5% |
| Chemicals Industry Average Movement | 4.4% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in DK Market | 7.2% |
| 10% least volatile stocks in DK Market | 2.3% |
Stable Share Price: NSIS B has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: NSIS B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 11,098 | Ester Baiget | www.novonesis.com |
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel.
Novozymes A/S Fundamentals Summary
| NSIS B fundamental statistics | |
|---|---|
| Market cap | DKK 197.78b |
| Earnings (TTM) | DKK 4.72b |
| Revenue (TTM) | DKK 32.12b |
Is NSIS B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NSIS B income statement (TTM) | |
|---|---|
| Revenue | €4.30b |
| Cost of Revenue | €1.87b |
| Gross Profit | €2.42b |
| Other Expenses | €1.79b |
| Earnings | €631.60m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 05, 2026
| Earnings per share (EPS) | 1.36 |
| Gross Margin | 56.39% |
| Net Profit Margin | 14.70% |
| Debt/Equity Ratio | 25.8% |
How did NSIS B perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 00:02 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novozymes A/S is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cezara Lozneanu | Barclays |
| Alexander Sloane | Barclays |
| Sebastian Satz | Barclays |